I-MED Surgical acquires exclusive rights to distribute the SOLX® Gold Shunt for Glaucoma in Canada
08/17/2010

I-MED Surgical, a division of I-MED Pharma, announced today that it is now the exclusive Canadian distributor of the SOLX® Glaucoma Treatment System. I-MED Surgical will begin a phased commercial launch of these new glaucoma shunts with full distribution expected by Q4 2010.

Online PR News – 17-August-2010 – – I-MED Surgical, a division of I-MED Pharma, announced today that it has acquired the exclusive rights to market and distribute the SOLX® Glaucoma Treatment System in Canada.

The SOLX® Gold Shunt is the next generation treatment platform that has the potential to change the current approach to glaucoma therapy. It provides a less invasive, yet highly effective glaucoma treatment for reducing Intraocular Pressure (IOP) associated with glaucoma in patients without creating a bleb.

The SOLX® Gold Shunt is the first biocompatible, 24-karat gold implant that uses the eye's natural pressure differential (uveal scleral outflow) to reduce intraocular pressure (IOP) without a bleb. It is approximately 3 mm wide, 6 mm long; it is about the thickness of a human hair. The Gold Shunt's thin structure is designed for implantation through a single micro-incision. It contains numerous micro-channels that bridge the anterior chamber and the suprachoroidal space, controlling aqueous outflow to reduce IOP. The shunt is virtually undetectable by the patient and is intended to last indefinitely.

The current SOLX® Gold Shunt GMS Plus model has the same outside dimensions are the same as the original Gold Shunt, however, the internal architecture incorporates a greater outflow facility (i.e., lower flow resistance) that provides lower intra-ocular pressure (IOP) with minimal glaucoma medications.

About I-MED

I-MED Pharma innovates and distributes medical, surgical and veterinary eye care products. I-MED remains uniquely focused on ophthalmology and is divided into three functional business units: Animal Health, Pharma and Surgical. It researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal transplants, dry eye, and glaucoma.

For more information please visit http://www.imedpharma.com

visit our website